BridgeBio Pharma, Inc. (BBIO)

NASDAQ • Healthcare

$74.84

-$0.56 (-0.8%)

Market closed

Last close at September 4, 2026 at 20:00 UTC

Day Range$74.11 - $75.36

Avg. Volume (3M)2M

Market Cap$14.6B

52 Week Range

$48.78$93.42

Next EarningsIn 54 daysOct 28, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$222.4M100%

Gross Profitminus cost of goods$207.3M93%

In plain terms: out of every $100 in revenue, BridgeBio Pharma, Inc. currently loses $68.

Fundamentals & Financials

Revenue (TTM)

$691.8M

Net Income (TTM)

-$696.2M

EPS (TTM)

-$3.58

ROA (TTM)

-57.2%

Current Ratio

1.23

Dividend Yield

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

-14.5%Q3 2025-$0.95

-8.0%Q4 2025-$0.95

-40.2%Q1 2026-$1

-23.8%Q2 2026-$0.84

-35.5%Q3 2026-$0.78

Oct 28

in 54 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

View full earnings history

About BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. is a NASDAQ-listed biotechnology company that develops medicines for genetic diseases, cancer-related conditions, and gene therapy applications. In FY2025, it generated $502.1 million of revenue. Founded in 2015 and based in Palo Alto, California, BridgeBio builds its business around a broad clinical pipeline and partnered research base.

Name

BridgeBio Pharma, Inc.

CEO

Neil Kumar

Website

www.bridgebio.com

Industry

Healthcare

Year Founded

2015

Employees

999

Today's Snapshot

AI-generated

The day ended with BBIO 0.8% lower at 74.84, in line with a weaker sector. BridgeBio Pharma reported data suggesting acoramidis, its heart drug, improved cardiac structure and function.

Trading Volume

Above 10d avg 1.5M

1.5M

vs S&P 500 Today

Moderate Underperformance

-0.34%

Updated: September 4, 2026 at 20:02 UTC

Technical Indicators

2 Buy1 Neutral5 Sell

BBIO’s chart leans bearish as multiple momentum indicators and MACD are negative and price sits below most short- and intermediate-term averages, with the classic pivot above the market reinforcing resistance. Trend strength is subdued with ADX under 20, and volatility is moderate, so downside pressure has been steady rather than volatile. On-balance volume readings are weak, reflecting distribution, even though a few very short-term oscillators show oversold bounces. Technical takeaway: Sell — prevailing momentum and volume point to continued technical downside pressure.

All signals